Literature DB >> 23454800

Infectivity enhancement of different HIV-1-based lentiviral pseudotypes in presence of the cationic amphipathic peptide LAH4-L1.

David Fenard1, Sandrine Genries, Daniel Scherman, Anne Galy, Samia Martin, Antoine Kichler.   

Abstract

Lentiviral vectors (LVs) are promising delivery systems for gene therapy. To enhance the efficiency of target cell transduction by LVs, protocols often include the addition of culture additives. In this study, the cationic amphipathic peptide LAH4-L1 (KKALLAHALHLLALLALHLAHALKKA), a DNA transfection agent, was evaluated for its capacity to improve LV infectivity in cell lines and primary cells. Results show that LAH4-L1 enhances infectivity of all LV pseudotypes tested, particularly GALVTR-LVs. More importantly, LAH4-L1 promotes the transduction of CD34+ hematopoietic stem cells with GALVTR-LVs as efficiently as Retronectin, a culture additive used in ex vivo clinical protocols involving LVs. The action of LAH4-L1 relies both on the GALVTR-LV adhesion and post-adhesion steps. LAH4-L1 represents a new and attractive transduction enhancer for hematopoietic gene therapy protocols.
Copyright © 2013 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23454800     DOI: 10.1016/j.jviromet.2013.02.005

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  7 in total

1.  Peptides derived from evolutionarily conserved domains in Beclin-1 and Beclin-2 enhance the entry of lentiviral vectors into human cells.

Authors:  Saliha Majdoul; Jeremie Cosette; Ababacar K Seye; Eric Bernard; Sophie Frin; Nathalie Holic; Nathalie Chazal; Laurence Briant; Lucile Espert; Anne Galy; David Fenard
Journal:  J Biol Chem       Date:  2017-09-19       Impact factor: 5.157

2.  Concurrent measures of fusion and transduction efficiency of primary CD34+ cells with human immunodeficiency virus 1-based lentiviral vectors reveal different effects of transduction enhancers.

Authors:  Dina Ingrao; Saliha Majdoul; Ababacar K Seye; Anne Galy; David Fenard
Journal:  Hum Gene Ther Methods       Date:  2013-11-20       Impact factor: 2.396

Review 3.  Gene Therapy for Beta-Hemoglobinopathies: Milestones, New Therapies and Challenges.

Authors:  Valentina Ghiaccio; Maxwell Chappell; Stefano Rivella; Laura Breda
Journal:  Mol Diagn Ther       Date:  2019-04       Impact factor: 4.074

4.  Molecular Determinants of Vectofusin-1 and Its Derivatives for the Enhancement of Lentivirally Mediated Gene Transfer into Hematopoietic Stem/Progenitor Cells.

Authors:  Saliha Majdoul; Ababacar K Seye; Antoine Kichler; Nathalie Holic; Anne Galy; Burkhard Bechinger; David Fenard
Journal:  J Biol Chem       Date:  2015-12-14       Impact factor: 5.157

5.  Vectofusin-1 Promotes RD114-TR-Pseudotyped Lentiviral Vector Transduction of Human HSPCs and T Lymphocytes.

Authors:  Claudia Piovan; Virna Marin; Cinzia Scavullo; Stefano Corna; Erica Giuliani; Sergio Bossi; Anne Galy; David Fenard; Claudio Bordignon; Gian Paolo Rizzardi; Chiara Bovolenta
Journal:  Mol Ther Methods Clin Dev       Date:  2017-03-08       Impact factor: 6.698

Review 6.  The Utilization of Cell-Penetrating Peptides in the Intracellular Delivery of Viral Nanoparticles.

Authors:  Jana Váňová; Alžběta Hejtmánková; Marie Hubálek Kalbáčová; Hana Španielová
Journal:  Materials (Basel)       Date:  2019-08-22       Impact factor: 3.623

7.  Different Biological Activities of Histidine-Rich Peptides Are Favored by Variations in Their Design.

Authors:  Morane Lointier; Candice Dussouillez; Elise Glattard; Antoine Kichler; Burkhard Bechinger
Journal:  Toxins (Basel)       Date:  2021-05-20       Impact factor: 4.546

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.